BCL2 and neoplasm: Beyond BRAFV600E mutation, HC express the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein, a well-studied inhibitor of cell death that sustains cell survival, tumor growth and cancer disease progression (15–17).